Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02305888 · ClinicalTrials.gov registry record · Phase 2
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT02305888 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 189 participants.
The verdict
NCT02305888, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively.
Interventions
- DRUG LEO 43204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02305888
The ClinicalTrials.gov registry entry for NCT02305888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LEO 43204 is the first listed.
NCT02305888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02305888 about?
NCT02305888 is a clinical study titled "Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively". The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively.
What is the current status of trial NCT02305888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2015-03. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02305888?
The interventions under investigation include: LEO 43204 (DRUG).
Who is sponsoring clinical trial NCT02305888?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.